Recently, Chinese surgical robotics company Surgo Technologies announced the completion of a $100 million Series D financing round, co-led by several prominent investment firms. The proceeds will primarily support the clinical rollout, product iteration, and global expansion of its single-port laparoscopic surgical robot system. Since its inception, Surgo has focused on independently developing high-precision, flexible surgical robotics technology. Its flagship product has already received market approval from China’s National Medical Products Administration (NMPA) and is being used clinically in multiple top-tier hospitals. This funding round underscores strong investor confidence in Surgo’s technological capabilities and commercial potential, marking a significant milestone for domestically developed high-end medical equipment on the global stage. Moving forward, Surgo plans to broaden its range of approved surgical indications and drive greater accessibility of robotic-assisted surgery, advancing ‘Made in China’ innovation worldwide.As one of the few domestic companies with full-stack proprietary technology in surgical robotics, Surgo’s continued advancements are poised to challenge long-standing foreign dominance in this field, offering patients safer, more precise, and minimally invasive surgical options.
近日，中国手术机器人企业术锐（Surgo Technologies）宣布完成1亿美元的D轮融资，由多家知名投资机构联合领投。本轮融资将主要用于加速其单孔腔镜手术机器人系统的临床推广、产品迭代及全球化布局。术锐自成立以来，始终专注于自主研发高精度柔性手术机器人技术，其核心产品已获得国家药监局（NMPA）批准上市，并在多家三甲医院开展临床应用。此次融资不仅体现了资本市场对其技术实力和商业化前景的高度认可，也标志着国产高端医疗装备在国际竞争中迈出关键一步。未来，术锐计划进一步拓展适应症范围，推动手术机器人普惠化，助力中国智造走向全球。作为国内少数掌握全链条核心技术的手术机器人公司，术锐的持续突破有望打破国外企业在该领域的长期垄断，为患者提供更安全、精准、微创的手术解决方案。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/8407.html